Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Argenica Therapeutics Ltd ( (AU:AGN) ).
Argenica Therapeutics Limited has issued 10,522 fully paid ordinary shares following the exercise of unlisted options, with a $0.65 exercise price. This move is part of the company’s compliance with the Corporations Act, allowing these shares to be sold without disclosure under certain exemptions, potentially enhancing liquidity and investor engagement.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited operates within the biotechnology industry, focusing on the development of novel therapeutics. The company is primarily engaged in creating treatments aimed at protecting brain cells and improving recovery following neurological conditions such as stroke.
Average Trading Volume: 94,515
Technical Sentiment Signal: Buy
See more data about AGN stock on TipRanks’ Stock Analysis page.